|
1
|
Kuru D, Argüden Tarkan Y, Ar M, Çırakoğlu
A, Öngören Ş, Yılmaz Ş, Eşkazan A, Deviren A, Soysal T,
Hacıhanefioğlu S and Ülkü B: Variant Philadelphia translocations
with different breakpoints in six chronic myeloid leukemia
patients. Turk J Haematol. 28:186–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aliano S, Cirmena G, Fugazza G, Bruzzone
R, Palermo C and Sessarego M: Standard and variant Philadelphia
translocation in a CML patient with different sensitivity to
imatinib therapy. Leuk Res Rep. 2:75–78. 2013.PubMed/NCBI
|
|
3
|
Sawyers CL: Chronic myeloid leukemia. N
Engl J Med. 17:1330–1340. 1999. View Article : Google Scholar
|
|
4
|
Cervantes F, Villamor N, Esteve J, Montoto
S, Rives S, Rozman C and Montserrat E: ‘Lymphoid’ blast crisis of
chronic myeloid leukaemia is associated with distinct
clinicohaematological features. Br J Haematol. 100:123–128. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Milojkovic D and Apperley J: Mechanisms of
resistance to imatinib and second-generation tyrosine inhibitors in
chronic myeloid leukemia. Clin Cancer Res. 15:7519–7527. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johansson B, Fioretos T and Mitelman F:
Cytogenetic and molecular genetic evolution of chronic myeloid
leukemia. Acta Haematol. 107:76–94. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abdulsalam AH, Nadal-Melsio E and Naresh
KN: Complementarity of evaluation of myeloperoxidase expression by
flow cytometry and immunohistochemistry on bone marrow trephine
biopsy sections in acute myeloid leukemia. Cytometry B Clin Cytom.
86:70–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Claussen U, Michel S, Mühlig P, Westermann
M, Grummt UW, Kromeyer-Hauschild K and Liehr T: Demystifying
chromosome preparation and the implications for the concept of
chromosome condensation during mitosis. Cytogenet Genome Res.
98:136–146. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simons A, Shaffer LG and Hastings RJ:
Cytogenetic nomenclature: Changes in the ISCN 2013 compared to the
2009 edition. Cytogenet Genome Res. 141:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siu LL, Ma ES, Wong WS, Chan MH and Wong
KF: Application of tri-colour, dual fusion fluorescence in situ
hybridization (FISH) system for the characterization of BCR-ABL1
fusion in chronic myelogenous leukaemia (CML) and residual disease
monitoring. BMC Blood Disord. 9:42009.PubMed/NCBI
|
|
11
|
Jobbagy Z, van Atta R, Murphy KM, Eshleman
JR and Gocke CD: Evaluation of the Cepheid GeneXpert BCR-ABL assay.
J Mol Diagn. 9:220–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beà S, López-Guillermo A, Ribas M, Puig X,
Pinyol M, Carrió A, Zamora L, Soler F, Bosch F, Stilgenbauer S, et
al: Genetic imbalances in progressed B-cell chronic lymphocytic
leukemia and transformed large-cell lymphoma (Richter's syndrome).
Am J Pathol. 161:957–968. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mullighan CG, Goorha S, Radtke I, Miller
CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds
SB, et al: Genome-wide analysis of genetic alterations in acute
lymphoblastic leukaemia. Nature. 446:758–764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haidar MA, Cao XB, Manshouri T, Chan LL,
Glassman A, Kantarjian HM, Keating MJ, Beran MS and Albitar M:
p16INK4A and p15INK4B gene deletions in primary leukemias. Blood.
86:311–315. 1995.PubMed/NCBI
|
|
15
|
Mrózek K, Harper DP and Aplan PD:
Cytogenetics and molecular genetics of acute lymphoblastic
leukemia. Hematol Oncol Clin North Am. 23:991–1010. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yanada M, Takeuchi J, Sugiura I, Akiyama
H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S,
et al: Karyotype at diagnosis is the major prognostic factor
predicting relapse-free survival for patients with Philadelphia
chromosome-positive acute lymphoblastic leukemia treated with
imatinib-combined chemotherapy. Haematologica. 93:287–290. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kliman D, Barnett M, Broady R, Forrest D,
Gerrie A, Hogge D, Nantel S, Narayanan S, Nevill T, Power M, et al:
Pediatric-based versus adult treatment protocols in young adults
(18-40 years) with standard risk acute lymphoblastic leukemia: The
BC cancer agency experience. Blood. 126:37702015.
|
